MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding

Clinical and Experimental Metastasis

Volumn 33, Issue 6, 2016, Pages 609-627

  Ruma, I Made Winarsa ^a,h   Putranto, Endy Widya ^a,i   Kondo, Eisaku ^b   Murata, Hitoshi ^a   Watanabe, Masami ^c   Huang, Peng ^c   Kinoshita, Rie ^a   Futami, Junichiro ^d   Inoue, Yusuke ^e   Yamauchi, Akira ^f   Sumardika, I Wayan ^a,h   Youyi, Chen ^a   Yamamoto, Ken Ichi ^a   Nasu, Yasutomo ^c   Nishibori, Masahiro ^a   Hibino, Toshihiko ^g   Sakaguchi, Masakiyo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e GUNMA UNIVERSITY   (Japan)

^f KAWASAKI MEDICAL SCHOOL   (Japan)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

^h UDAYANA UNIVERSITY   (Indonesia)

ⁱ GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

ALCAM; Malignant melanoma; MCAM; NF B; RAGE; S100A8 A9

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALGRANULIN A; CALGRANULIN B; CD146 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; AGER PROTEIN, HUMAN; ALCAM PROTEIN, HUMAN; FETOPROTEIN; LEUKOCYTE ANTIGEN; MCAM PROTEIN, HUMAN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIGAND BINDING; LUNG METASTASIS; MALE; MELANOMA; MELANOMA CELL LINE; MOUSE; NEVUS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL ADHESION; CELL MOTION; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ANTIGENS, CD; ANTIGENS, CD146; APOPTOSIS; BLOTTING, WESTERN; CALGRANULIN A; CALGRANULIN B; CELL ADHESION; CELL ADHESION MOLECULES, NEURONAL; CELL MOVEMENT; CELL PROLIFERATION; FETAL PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; NF-KAPPA B; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84966349250     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-016-9801-2     Document Type: Article

References (83)

1. Greten FR et al (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296
2. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
3. Ruegg C (2006) Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. J Leukoc Biol 80:682–684
4. Gebhardt C, Breitenbach U, Tuckermann JP et al (2002) Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene 21:4266–4276
5. Ott HW, Lindner H, Sarg B et al (2003) Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 63:7507–7514
6. Gebhardt C, Nemeth J, Angel P et al (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72:1622–1631
7. Salama I, Malone PS, Mihaimeed F et al (2008) A review of the S100 proteins in cancer. Eur J Surg Oncol 34:357–364
8. Kerkhoff C, Voss A, Scholzen TE et al (2012) Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol 21:822–826
9. Arai K, Takano S, Teratani T (2008) S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 8:243–252
10. Katz AB, Taichman LB (1999) A partial catalog of proteins secreted by epidermal keratinocytes in culture. J Invest Dermatol 112:818–821
11. Thorey IS, Roth J, Regenbogen J et al (2001) The Ca2+ -binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes. J Biol Chem 276:35818–35825
12. Foell D, Frosch M, Sorg C et al (2004) Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 344:37–51
13. Robinson MJ, Tessier P, Poulsom R et al (2002) The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 277:3658–3665
14. Vogl T, Tenbrock K, Ludwig S et al (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13:1042–1049
15. Srikrishna G, Panneerselvam K, Westphal V et al (2001) Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells. J Immunol 166:4678–4688
16. Ghavami S, Rashedi I, Dattilo BM et al (2008) S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 83:1484–1492
17. Turovskaya O, Foell D, Sinha P et al (2008) RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29:2035–2043
18. Ichikawa M, Williams R, Wang L et al (2011) S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 9:133–148
19. Yin C, Li H, Zhang B et al (2013) RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial–mesenchymal transition. Breast Cancer Res Treat 142:297–309
20. Hermani A, De Servi B, Medunjanin S et al (2006) S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312:184–197
21. Chen B, Miller AL, Rebelatto M et al (2015) S100A9 Induced Inflammatory Responses Are Mediated by Distinct Damage Associated Molecular Patterns (DAMP) Receptors In Vitro and In Vivo. PLoS ONE 10:e0115828
22. Albelda SM (1993) Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68:4–17
23. Al-Mehdi AB, Tozawa K, Fisher A et al (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 6:100–101
24. Pollard TD, Earnshaw WC (2002) Cellular adhesion. Cell biology, 6th edn. Saunders, Philadelphia, p 507–524
25. Yang Y, Jun CD, Liu JH et al (2004) Structural basis for dimerization of ICAM-1 on the cell surface. Mol Cell 14:269–276
26. Sessa L, Gatti E, Zeni F et al (2014) The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS ONE 9:e86903
27. Holzmann B, Brbcker EB, Lehmann JM et al (1987) Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 39:466–471
28. Luca M, Hunt B, Bucana CD et al (1993) Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 3:35–41
29. Degen W, van Kempen L, Gijzen E et al (1998) MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 152:805–813
30. van Kempen LC, van den Oord JJ, van Muijen GN et al (2000) Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156:769–774
31. Kristiansen G, Pilarsky C, Wissmann C et al (2005) Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205:359–376
32. King JA, Ofori-Acquah SF, Stevens T et al (2004) Activated leukocyte cell adhesion molecule in breast cancer: Prognostic indicator. Breast Cancer Res 6:478–487
33. Davies SR, Dent C, Watkins G et al (2008) Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep 19:555–561
34. Weichert W, Knosel T, Bellach J et al (2004) ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57:1160–1164
35. Verma A, Shukla NK, Deo SV et al (2005) MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68:462–470
36. Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330:150–162
37. Wang J, Tang X, Weng W et al (2015) The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma. Oncogene 34:5781–5795
38. Sakaguchi M, Watanabe M, Kinoshita R et al (2014) Dramatic increase in expression of a transgene by insertion of promoters downstream of the cargo gene. Mol Biotechnol 56:621–630
39. Sakaguchi M, Murata H, Aoyama Y et al (2014) DNAX-activating protein 10 (DAP10) membrane adaptor associates with receptor for advanced glycation end products (RAGE) and modulates the RAGE-triggered signaling pathway in human keratinocytes. J Biol Chem 289:23389–23402
40. Bowen MA, Patel DD, Li X et al (1995) Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181:2213–2220
41. Gebhardt C, Riehl A, Durchdewald M et al (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205:275–285
42. Iotzova-Weiss G, Dziunycz PJ, Freiberger SN et al (2015) S100A8/A9 Stimulates keratinocyte proliferation in the development of squamous cell carcinoma of the skin via the receptor for advanced glycation-end products. PLoS ONE 10:e0120971
43. Sunahori K, Yamamura M, Yamana J et al (2006) The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthr Res Ther 8:R69
44. Meyskens FL Jr, Buckmeier JA, McNulty SE et al (1999) Activation of nuclear factor-kappa B in human metastatic melanoma cells and the effect of oxidative stress. Clin Cancer Res 5:1197–1202
45. Fried L, Arbiser JL (2008) The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 21:117–122
46. Zhang Y, Du Y, Le W et al (2011) Redox control of the survival of healthy and diseased cells. Antioxid Redox Signal 15:2867–2908. doi:10.1089/ars.2010.3685
47. Wu WS (2006) The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 25:695–705
48. Rapanotti MC, Suarez Viguria TM, Costanza G et al (2014) Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma. Arch Dermatol Res 306:527–537
49. Lehmann JM, Holzmann B, Breitbart EW et al (1987) Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein. with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47:841–845
50. Hiratsuka S, Watanabe A, Aburatani H et al (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8:1369–1375
51. Ang CW, Nedjadi T, Sheikh AA et al (2010) Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis 31:1541–1551
52. Saha A, Lee YC, Zhang Z et al (2010) Lack of an endogenous anti-inflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs. J Biol Chem 285:10822–10831
53. Sinha P, Okoro C, Foell D et al (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181:4666–4675
54. Wang L, Chang EW, Wong SC et al (2013) Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 190:794–804
55. Karin M, Cao Y, Greten FR et al (2002) NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–310
56. Morgan MJ, Liu ZG (2011) Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21:103–115
57. Mehdi MZ, Azar ZM, Srivastava AK (2007) Role of receptor and nonreceptor protein tyrosine kinases in H2O2-induced PKB and ERK1/2 signaling. Cell Biochem Biophys 47:1–10
58. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135–142
59. Luo Y, Ellis LZ, Dallaglio K et al (2012) Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol 132:2440–2450
60. Hibino T, Sakaguchi M, Miyamoto S et al (2013) S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res 73:172–183
61. Ribe A, McNutt NS (2003) S100A protein expression in the distinction between lentigo maligna and pigmented actinic keratosis. Am J Dermatopathol 25:93–99
62. Wu GJ, Fu P, Wang SW, Wu MW (2008) Enforced expression of MCAM/MUC18 increases in vitro motility and invasiveness and in vivo metastasis of two mouse melanoma K1735 sublines in a syngeneic mouse model. Mol Cancer Res 11:1666–1677
63. Mirkina I, Hadzijusufovic E, Krepler C et al (2014) Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4 EPO-R and NGF-R. PLoS ONE 1:e84417
64. Ishikawa T, Wondimu Z, Oikawa Y et al (2014) Laminins 411 and 421 differentially promote tumor cell migration via alpha6beta1 integrin and MCAM (CD146). Matrix Biol 38:69–83
65. Rapanotti MC, Ricozzi I, Campione E et al (2013) Blood MUC-18/MCAM expression in patients with melanoma: a suitable marker of poor outcome. Br J Dermatol 169:221–222
66. Rao C, Bui T, Connelly M et al (2011) Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 38:755–760
67. Khoja L, Lorigan P, Zhou C et al (2013) Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol 133:1582–1590
68. Ordonez NG (2014) Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum Pathol 2:191–205
69. Klinac D, Gray ES, Freeman JB et al (2014) Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer 14:423
70. Mills L, Tellez C, Huang S et al (2002) Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62:5106–5114
71. Yan X, Lin Y, Yang D et al (2003) A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102:184–191
72. Prosen L, Markelc B, Dolinsek T et al (2014) Mcam silencing with RNA interference using magnetofection has antitumor effect in murine melanoma. Mol Ther Nucleic Acids 3:e205
73. Kang Y, Massague J (2004) Epithelial–mesenchymal transitions: twist in development and metastasis. Cell 118:277–279
74. Todorovic V, Sersa G, Cemazar M (2013) Gene electro-transfer of siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28. Cancer Gene Ther 20:208–210
75. Wu Z, Wu Z, Li J et al (2012) MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol 33:1619–1628
76. Zabouo G, Imbert AM, Jacquemier J et al (2009) CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res 11:R1
77. Chen W, Zhang HL, Jiang YG et al (2009) Inhibition of CD146 gene expression via RNA interference reduces in vitro perineural invasion on ACC-M cell. J Oral Pathol Med 38:198–205
78. Bu P, Zhuang J, Feng J et al (2007) Visualization of CD146 dimerization and its regulation in living cells. Biochim Biophys Acta 1773:513–520
79. McGary EC, Lev DC, Bar-Eli M (2002) Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 5:459–465
80. Melnikova VO, Balasubramanian K, Villares GJ et al (2009) Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem 284:28845–28855
81. Yazawa EM, Geddes-Sweeney JE, Cedeno-Laurent F et al (2015) Melanoma cell galectin-1 ligands functionally correlate with malignant potential. J Invest Dermatol 135:1849–1862
82. Tu T, Zhang C, Yan H et al (2015) CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res 25:275–287
83. Ye Z, Zhang C, Tu T et al (2013) Wnt5a uses CD146 as a receptor to regulate cell motility and convergent extension. Nat Commun 4:2803